GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Float Percentage Of Total Shares Outstanding

Biovica International AB (OSTO:BIOVIC B) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 15, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biovica International AB's float shares is 0.00 Mil. Biovica International AB's total shares outstanding is 84.06 Mil. Biovica International AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biovica International AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biovica International AB's Institutional Ownership is 0.32%.


Biovica International AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Biovica International AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/84.06
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biovica International AB (OSTO:BIOVIC B) Business Description

Industry
Traded in Other Exchanges
Address
Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB (OSTO:BIOVIC B) Headlines

No Headlines